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Background. Population-based studies are needed to estimate the prevalence of underweight or overweight/obese childhood
cancer survivors. Procedure. Adult survivors (diagnosed ≤20 years) were identified from the linked Utah Cancer Registry and
Utah Population Database. We included survivors currently aged ≥20 years and ≥5 years from diagnosis (𝑁 = 1060), and a
comparison cohort selected on birth year and sex (𝑁 = 5410). BMI was calculated from driver license data available from 2000 to
2010. Multivariable generalized linear regression models were used to calculate prevalence relative risks (RR) and 95% confidence
intervals (95% CI) of BMI outcomes for survivors and the comparison cohort. Results. Average time since diagnosis was 18.5 years
(SD = 7.8), and mean age at BMI for both groups was 30.5 (survivors SD = 7.7, comparison SD = 8.0). Considering all diagnoses,
survivors were not at higher risk for being underweight or overweight/obese than the comparison. Male central nervous system
tumor survivors were overweight (RR = 1.12, 95% CI 1.01–1.23) more often than the comparison. Female survivors, who were
diagnosed at age 10 and under, had a 10% higher risk of being obese than survivors diagnosed at ages 16–20 (𝑃 < 0.05). Conclusion.
While certain groups of childhood cancer survivors are at risk for being overweight/obese, in general they do not differ from
population estimates.
1. Introduction
As of 2005, there were over 328,000 childhood cancer
survivors in the USA, a number that will continue to grow
with emerging treatment procedures [1]. Unfortunately,
survival from childhood cancer is often accompanied by
an increased risk for adverse late effects from treatment [2–4],
including cardiovascular risk [5, 6], insulin resistance [7], and
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neurologic, musculoskeletal, and pulmonary complications
[8]. Furthermore, adult survivors of childhood cancer may
be particularly prone to weight-related problems as approx-
imately half report low levels of physical activity [9, 10]. In
the general population, a high body mass index (BMI) in the
overweight or obese range is associated with an increased
risk for chronic health conditions including hypertension
[11], diabetes [12], cancer [13], and cardiovascular disease
[5, 14]. Late effects from treatment and low levels of physical
activity may compound the risk of additional weight-related
problems among survivors with abnormal BMIs.
There is a considerable body of evidence underscoring
the impact of early life exposures, such as a pediatric cancer
diagnosis, on health throughout the lifespan [4]. To date,
most USA studies describing childhood cancer survivors’
BMI have focused on samples of survivors diagnosed from
1970 to 1986 in the Childhood Cancer Survivor Study [15–
19]. As many of the treatment protocols have evolved since
that time, studies that include survivors diagnosed more
recently are needed. Additionally, much of the research on
childhood cancer survivors’ BMI has emerged from clinical
samples. With the high national prevalence of overweight
and obesity [20] and with weight-related health problems
emerging at younger ages [21], population-based studies
can provide important context for determining policy and
allocating resources to improve cancer survivors’ long-term
health.
Certain groups of childhood cancer survivors appear to
face a higher risk of being overweight or obese, including
survivors of acute lymphoblastic leukemia [22–24] and other
leukemias [15] as do patients who are diagnosed at a young
age [17–19, 25], female [18, 26], and recipients of cranial
radiation [16, 18, 19]. Conversely, other childhood cancer
survivors, such as those surviving Hodgkin disease and
Wilms tumor, may instead be at risk for being underweight as
adults [15]. For survivors of central nervous system tumors,
the literature is mixed with some studies reporting elevated
risk for being overweight or obese [25] as well as underweight
[27], and others suggesting the weight distribution among
these survivors is similar to that of the general population
[28].
We conducted a population-based evaluation of BMI
outcomes among adult survivors of childhood cancer. We
queried a cohort of childhood cancer survivors diagnosed
from 1973 to 2005 from the Utah Cancer Registry (UCR)
and a comparison cohort sample from the Utah Population
Database (UPDB) and Utah birth certificates. We hypothe-
sized that childhood cancer survivors would be more likely
to be overweight or obese in adulthood than the comparison
cohort and that groups at highest risk of obesity would
include leukemia survivors, female survivors, and those who
received radiation therapy.
2. Methods
2.1. Data Resources. The UPDB is a University of Utah
resource that contains over seven million individual records
from statewide datasets [29, 30].TheUPDB includes all driver
license records (as well as identification cards for nondrivers),
which we used to ascertain self-reported height and weight.
As over 80% of adults in the USA aged 20–70 have a driver
license [31], using these data to ascertain BMI provides a
high level of coverage typically unavailable through surveys,
which often have lower response rates [32]. To validate the
use of driver license data for BMI estimates, the UPDB
has compared age- and sex-specific mean BMI values with
two data sources, the 2000 Utah Behavioral Risk Factor
Surveillance Survey (BRFSS) and 155 individuals with clinical
measures of height and weight. BRFSS is used to assess BMI
and obesity trends in the US (http://www.cdc.gov/brfss/),
making it an appropriate data source to validate Utah driver
license data. BRFSS mean BMI values were only 1% and
3% higher for males and females, respectively, in relation to
driver license estimates.Therewas a high correlation between
clinical and self-reported driver license height and weight
(𝑟 = 0.85).
Cancer data were provided by the UCR, which has been
a part of the Surveillance, Epidemiology, and End Results
(SEER) Program of the National Cancer Institute since 1973.
The UCR records are linked to the UPDB, with over 97%
of individuals with cancer linked to one or more records
in the UPDB [33]. All study protocols and procedures were
approved by the University of Utah Institutional Review
Board and the Utah Resource for Genetic and Epidemiologic
Research.
2.2. Subject Sampling and Eligibility. A cohort of childhood
cancer survivors was identified from the linked UCR and
UPDB. A noncancer comparison cohort, with similar distri-
bution of birth year and sex, was sampled from Utah birth
certificates through the UPDB.
Childhood Cancer Cases. The UCR was queried for all
childhood cancer cases with a Utah birth certificate who
were diagnosed in Utah before age 21 from 1973 to 2005.
Eligible cases were diagnosed with a cancer that met the
International Classification of Childhood Cancer (ICCC)
criteria. The ICCC is the standard classification system for
childhood cancers. It is based on tumor morphology and
primary cancer site with an emphasis on morphology rather
than cancer site as for adults [34]. Nonmelanoma skin cancers
and cancers in situ were excluded. Ten cases were excluded
due to lack of information on their diagnosis. A total of𝑁 =
2743 unique individuals were identified (Figure 1).
Comparison Cohort. Noncancer participants were randomly
selected from Utah birth certificates, which were accessed
through the UPDB. The comparison sample was frequency
matched on birth year and sex using a three to one ratio of
comparison sample to cancer cases. A total of 𝑁 = 8259
unique individuals were identified (Figure 1).
Eligibility Criteria for Cancer Survivors and the Comparison
Cohort. We limited our sample to individuals who survived
to at least age 20 at the time of their most recent driver
license record, because 20 is the minimum age for adult
BMI calculations according to the National Heart, Lung,
and Blood Institute (NHLBI) [35]. Other eligibility criteria
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Cancer survivors Comparison cohort
from 1973–2005
∙ Not meeting ICCCa
criteria
∙ Deceased prior to 2000 (N = 669)
∙ Deceased 2000–2010, prior to
receiving or obtaining initial DLb
(N = 86)
DL record (N = 340)
∙ No longer living in Utah/had not
renewed or obtained DL during
2000–2010 (N = 371)
∙ Bone tumor (N = 59)
∙ Deceased prior to 2000 (N = 49)
∙ Deceased 2000–2010, prior to
receiving or obtaining initial DL
(N = 57)
DL record (N = 1541)
∙ No longer living in Utah/had not
renewed or obtained DL during
2000–2010 (N = 1202)
Final sample
N = 1060 cancer sample
N = 5410 comparison sample
N = 2743 N = 8259
∙ Deceased when index
case diagnosed with
cancer
∙ Not still living in Utah
when index case
diagnosed with cancer
1 : 3 selection based on birth year and sex
∙
∙ <5 years past diagnosis (N = 158)
∙ <20 years at time of most recent
∙ <20 years at time of most recent
∙ Diagnosed ≥21 years
Nonmelanoma and in
situ cancers
Figure 1: Sample exclusion criteria. aInternational Classification of Childhood Cancers, bDriver License.
included Utah driver license renewal during 2000–2010.
Individuals in Utah are required by law to renew their
driver license every five years and in person every ten years.
Therefore, this ten-year date range captures at least one driver
license renewal where driver license height and weight were
updated. We excluded those who were either no longer living
in Utah or had not renewed or obtained their initial driver
license from 2000 to 2010. The survivor sample was also
limited to those ≥5 years from diagnosis to ensure that a
majority had completed their cancer therapy. Additionally,
we excluded 𝑁 = 59 bone cancer patients as we lacked
information on amputations or limb-sparing therapy which
can potentially affect weight and height. A total of𝑁 = 1060
survivors and 𝑁 = 5410 in the comparison cohort were
available for analysis.
2.3. Demographic Measures. Sex and race/ethnicity were
obtained from UPDB records. Age at BMI was calculated
using the date seen in person for driver license renewal and
date of birth.
2.4. Cancer-Related Measures. For cancer cases, the UCR
provided data on diagnosis, date of diagnosis, age at diag-
nosis, receipt of surgery, chemotherapy and/or radiation as
part of their first course therapy, and whether the individual
had more than one primary cancer diagnosis. Time since
diagnosis was calculated using BMI date and date of cancer
diagnosis. Cancer diagnoses included lymphomas, leukemias
(grouped as “other leukemia” and “acute lymphoblastic
leukemia” (ALL)), central nervous system neoplasms (CNS),
epithelial cancers (malignancies such as thyroid cancers and
melanomas), germ/gonadal cancers, sarcomas, renal tumors,
neuroblastomas, and retinoblastomas. Cancer treatment was
categorized as eight mutually exclusive groups: surgery only,
chemotherapy only, radiation only, chemotherapy/radiation,
chemotherapy/surgery, radiation/surgery, and chemother-
apy/radiation/surgery, and not documented/no treatment.
Second primary cancers were also tabulated (yes/no).
2.5. BMI Outcomes. The primary outcome of interest was
BMI. Using the height and weight that were self-reported at
the most recent driver license renewal, BMI was calculated
as weight in kg/height in m2. We classified BMI according
to the NHLBI standards: underweight (<18.5 kg/m2), normal
(18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), and obese
(≥30 kg/m2) [36]. For our main analyses, abnormal BMIs
were considered as underweight (BMI < 18.5) and over-
weight/obese (defined as BMI ≥ 25). These were evaluated
as dichotomous outcomes with the other BMI categories as
the referent (e.g., underweight versus normal-obese) to be
comparable to other childhood cancer studies of BMI [15].
As a secondary analysis, obese (BMI ≥ 30) was analyzed as a
dichotomous outcome compared to nonobese.
2.6. Statistical Analyses. All analyses were generated using
statistical software, Stata 12.1. Descriptive statistics were cal-
culated for demographic and cancer-related characteristics.
Age at BMI, sex, and race/ethnicity distributions of the
survivors and the comparison groupwere summarized in cat-
egories and tested using 𝜒2. Proportions were calculated for
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cancer-related factors (i.e., diagnosis, age at diagnosis, years
since diagnosis, treatment, and second primary cancers).
Multivariable generalized linear regression models with
robust standard errors were used to calculate prevalence
relative risks (RR) and 95% confidence intervals (95% CI)
both for survivors compared to the comparison cohort and
for analyses limited to survivors only. A Gaussian family
with identity link was used due to problems with model
convergence using a binomial distribution. As BMI differs by
sex [37], all analyses were run separately by sex. All models
included an interaction term for continuous birth year and
categorical age at BMI and were controlled for year at BMI
measurement. We first estimated models to compare the
outcomes of underweight and overweight/obese for the full
cancer sample to the comparison sample. Then, to exam-
ine differences by diagnosis, we estimated regressions only
among the top fivemost common cancer groups (lymphoma,
epithelial, ALL, CNS, and germ cell) due to sample size
limitations.
In our last set of models, we evaluated predictors
of being underweight or overweight/obese among cancer
survivors. Predictors of interest included age at diagnosis,
race/ethnicity, and treatment type, as these factors have been
associated with abnormal BMI in other childhood cancer
studies [15]. As a secondary analysis, we examined obese
(BMI ≥ 30) as a separate outcome for the survivor-only
models. Also, as wewere interested in understandingwhether
survivors with more recent diagnoses might have differences
in BMI, these models were reestimated for those diagnosed
1990 and after. As themajority of our variables of interest were
ascertained from birth and cancer registry records, missing
data were minimal (less than 10% for most), so no analytics
were used to address the potential bias due to missing data.
3. Results
Age, sex, and race/ethnicity did not differ significantly
between survivors and the comparison cohort in Table 1.
Average time since diagnosis was 18.5 (SD = 7.8), and mean
age at BMI was 30.5 for both the survivors (SD = 7.7) and
comparison group (SD = 8.0). Surgery only (23.1%) and
chemotherapy only (19.5%)were themost common treatment
groups. In Table 2, the most common cancers among female
survivors were epithelial (26.1%) and lymphoma (17.4%), and
formales, lymphoma (23.8%) andCNS tumors (16.3%).There
were no differences between the combined survivor group
and the comparison group in distributions of BMI categories
(underweight, normal, overweight, and obese).
3.1. BMI among Cancer Survivors and Comparison Cohort
for the Five Most Common Cancer Diagnoses. We estimated
models comparing survivors to the comparison cohort for
the overall cancer sample and by cancer diagnosis in Table 3.
For the overall survivor group, there were no differences for
either female ormale survivors versus the comparison cohort
in their risk of being underweight or overweight/obese.
However, when examined by cancer diagnosis, female epithe-
lial survivors were less likely to be overweight or obese
(RR = 0.89, 95% CI 0.82–0.96) than the comparison. Among
males, CNS tumor survivors had a slightly higher risk of being
overweight or obese (RR = 1.12, 95% CI 1.01–1.23) than the
comparison.
3.2. BMI Outcomes among Cancer Survivors by Age at
Diagnosis, Race/Ethnicity, and Treatment Therapy. We then
estimated regressionmodels for survivors only to evaluate the
impact of age at diagnosis, race/ethnicity, and cancer therapy
on risk of being underweight or overweight/obese in separate
models by sex in Table 4. In our main models we found that,
for female survivors, cancer therapy was not significantly
associated with being underweight or overweight/obese.
Younger diagnosis age was marginally significant for being
overweight/obese for females aged 5–10 years at diagnosis
(RR = 1.14, 95% CI 1.00–1.31) compared to ages 16–20,
and the test for trend across age groups was significant at
𝑃 = 0.03. Non-Hispanic White female survivors tended to
be underweight (RR = 1.09, 95% CI 1.04–1.15) more often
than survivors of Other races. No factors were statistically
significant in the male survivors’ models.
As a secondary analysis, we also examined the risk of
being obese among survivors. Female survivors diagnosed
aged ≤4 years (RR = 1.12, 95% CI 1.03–1.22) and 5–10 years
(RR = 1.10, 95% CI 1.01–1.21) were at higher risk for being
obese when compared to those diagnosed aged 16–20 years
(𝑃 value test for trend 𝑃 = 0.004). Non-Hispanic White
female survivors were more likely to be obese than female
survivors of other races (RR = 1.11, 95% CI 1.04–1.19).
Female survivors with chemotherapy and surgery had a lower
risk of obesity (RR = 0.90, 95% CI 0.84–0.96) compared to
patients receiving only surgery. Finally, when we restricted
our analyses to survivors diagnosed after 1990, no differences
emerged in the impact of age, race/ethnicity, and cancer
therapy on risk of being underweight or overweight/obese for
either female or male survivors.
4. Discussion
This study is one of the first population-based evaluations
of prevalence of underweight and overweight/obese adult
survivors of childhood cancer. Our findings expand on earlier
studies by utilizing a large state-level sample of survivors
diagnosed from 1973 to 2005. We found that, among adult
survivors of childhood cancer in Utah, 36% of females and
61% of males had BMIs that categorized them as overweight
or obese, although these prevalences were similar to an
age- and sex-matched comparison cohort from the gen-
eral population. Other studies have reported that survivors’
prevalence of overweight is not higher than population-based
controls [24]. In addition, although treatment protocols have
changed during the past decades, we found no differences
in the impact of cancer therapy when examining survivors
diagnosed after 1990.
Few differences in BMI were found by cancer diagnosis.
Female survivors of epithelial cancers were less likely to be
overweight or obese in reference to the comparison cohort.
Only male CNS tumor survivors were at an elevated risk of
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Table 1: Demographics and cancer-related factors for survivors and the comparison cohort.
Cancer survivors Comparison cohort
(𝑁 = 1060) (𝑁 = 5410) 𝑃 value
𝑁 % 𝑁 %
Age at body mass index
18–29 565 53.3 2953 54.6
0.6230–39 351 33.1 1709 31.6
≥40 144 13.6 748 13.8
Sex
Female 518 48.8 2665 49.2 0.82
Male 542 51.2 2745 50.7
Race/ethnicity
White, Non-Hispanic 1036 97.6 5261 97.1 0.37
Other 24 2.4 149 2.8
Birth year
1952–1960 59 5.6 320 5.9
0.401961–1970 181 17.1 913 16.9
1971–1980 468 44.1 2253 41.7
1981–1990 352 33.2 1924 35.6
Diagnosis age (years)
≤4 214 20.9



















Chemotherapy + radiation 149 14.1
Chemotherapy + surgery 73 6.9
Radiation + surgery 52 4.9
Chemotherapy + radiation + surgery 45 4.3
Second primary cancers
No 1052 99.2 NA NA
Yes 8 0.8
being overweight or obese, similar to prior research [25].This
finding is not surprising as the treatment for brain tumors
often includes cranial radiation. As a result, hypothalamic
function can be affected, which may potentially predispose
these survivors to weight problems at a higher rate than other
childhood cancer survivors [38]. Conversely, while an earlier
report from the Childhood Cancer Survivor Study found
that leukemia survivors were more often obese compared
to population norms [15] neither ALL nor other leukemia
survivors in our sample showed differences.
Although our findings suggest that most childhood can-
cer survivors are not at an elevated risk for abnormal BMI,
we did see that certain groups of survivors face a higher risk
of obesity. Specifically, female survivors diagnosed between
the ages of 0 and 10 years had a modest increased risk of
obesity when compared to those diagnosed at older ages,
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Table 2: Body Mass Index proportions for survivors by cancer type and comparison cohort.
Body Mass Index
Total Underweight Normal Overweight Obese
BMI < 18.5 BMI 18.5–24.9 BMI 25–29.9 BMI ≥ 30 𝑃 value
𝑁 % 𝑁 % 𝑁 % 𝑁 % 𝑁 %
Female
Comparison sample n/a 123 4.6 1551 58.2 598 22.4 393 14.8 0.06b
All cancers n/a 33 6.4 296 57.1 130 25.1 59 11.4
Diagnosis groups
Lymphoma 90 17.4 8 8.9 53 58.9 22 24.2 7 7.0
Epithelial 135 26.1 7 5.2 87 64.4 25 18.5 16 11.9
ALLa 82 15.9 6 7.3 43 52.4 22 27.1 11 13.4
Central nervous system 67 13.0 4 6.0 36 53.7 17 25.4 10 14.9
Germ 34 6.6 0 0.0 22 61.8 11 33.3 2 5.9
Sarcoma 41 7.9 5 12.2 19 46.3 13 31.7 4 9.7
Renal 25 4.8 1 4.0 13 52.0 8 32.0 3 12.0
Neuroblastoma 16 3.1 0 0.0 9 56.3 4 25.0 3 18.8
Other leukemia 14 2.7 1 7.1 8 57.1 3 21.4 2 14.3
Retinoblastoma 13 2.5 1 7.7 7 53.9 4 30.8 1 7.7
Male
Comparison sample n/a 31 1.1 1102 40.2 1083 39.5 529 19.3 0.13c
All cancers n/a 11 2.0 198 36.6 216 39.9 117 21.6
Diagnosis groups
Lymphoma 129 23.8 1 0.8 46 35.6 51 39.5 31 24.0
Epithelial 64 11.8 1 1.6 22 34.4 26 40.6 15 23.4
ALLa 83 15.3 2 2.4 33 39.8 32 38.6 32 19.3
Central nervous system 88 16.3 0 0.0 28 31.8 35 39.8 25 28.4
Germ 83 15.3 4 4.8 35 42.2 29 34.9 15 18.1
Sarcoma 36 6.7 0 0.0 15 41.7 14 38.9 7 19.4
Renal 25 4.6 0 0.0 5 20.0 16 64.0 4 16.0
Neuroblastoma 18 3.3 1 5.6 9 50.0 6 33.3 2 11.1
Other leukemia 11 2.0 1 9.1 4 36.4 6 54.6 0 0.0
Retinoblastoma 4 0.7 1 25.0 0 0.0 1 25.0 2 50.0
aAcute lymphoblastic leukemia.
bComparing full female comparison cohort to full female cancer group.
cComparing full male comparison cohort to full male cancer group.
concurrent with findings from prior studies [17–19, 25]. A
similarly elevated risk was found for Non-Hispanic White
female survivors compared to survivors of Other races.
However, due to the small proportion of Other race/ethnicity
participants, we are limited in understanding the implications
of this finding. In the future, particular focus should be
given to developing population-based studies that include
more racially/ethnically diverse survivor populations as, in
the general population, they tend to have higher BMIs than
Non-Hispanic Whites [23]. In addition, women historically
have had higher rates of overweight/obesity in the USA, yet
in recent years (i.e., 2009-2010) this difference subsided [20].
In Utah, substantially more men are overweight or obese
(70%) than women (52%) [39]. Similarly, we found thatmales
in both the survivor and comparison sample had higher
proportions of overweight/obese than females.
Our study has limitations. First, we did not have
detailed information on cancer therapy (e.g., amputations,
chemotherapy type, and duration of therapy) limiting our
ability to identify the effect of specific therapies on BMI.
Second, driver license data is self-reported and may not be as
accurate as clinical methods of measuring BMI. Third, more
women underreport their weight than men [40]. Fourth,
although self-reported data tend to underestimate BMI values
in relation to clinical data, as discussed earlier, the UPDB’s
validation of Utah driver license data to BRFSS and a clinical
sample found BMI to be comparable across the data sources.
Fifth, thematching of survivors to the comparison cohort was
done early in the selection process.Thedatawere selected and
matched using several different statewide data sources, and
due to practical limitations, it was not possible to impose all of
the exclusions at the initiation of the study. However, despite
this limitation, the two samples are very similar on age and
sex.
Though still high, Utah has a lower prevalence of
overweight and obesity than the US population [41]. We
evaluated BMI at only one time point; thus, our results
could be affected by survivor bias. While we have no reason
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Table 3: Relative risks (RR) and 95% confidence intervals (95%CI) of BMI outcomes for all cancers and the fivemost common cancers versus
comparison cohorta.
Underweight Overweight/obese
(BMI < 18.5)a,b (BMI ≥ 25)a,c
RR 95% CI 𝑃-value RR 95% CI 𝑃-value
Female
Comparison cohort (ref) 1 1
All cancers 1.02 1.00–1.04 0.10 0.99 0.94–1.03 0.58
Top five cancers
Lymphoma 1.05 0.98–1.11 0.14 0.94 0.86–1.04 0.24
Epithelial 1.01 0.98–1.05 0.44 0.89 0.82–0.96 0.004
Acute lymphoblastic leukemiab 1.02 0.96–1.08 0.47 1.07 0.96–1.19 0.22
Central nervous system 1.01 0.96–1.07 0.69 1.03 0.92–1.16 0.58
Germ n/ad 0.97 0.82–1.14 0.70
Male
Comparison cohort (ref) 1 1
All cancers 1.01 1.00–1.02 0.16 1.02 0.98–1.07 0.28
Top five cancers
Lymphoma 1.00 0.98–1.01 0.74 1.03 0.95–1.11 0.52
Epithelial 1.01 0.98–1.04 0.61 1.00 0.89–1.13 0.99
Acute lymphoblastic leukemia 1.01 0.98–1.04 0.58 1.03 0.93–1.13 0.54
Central nervous system n/ad 1.12 1.01–1.23 0.03
Germ 1.04 0.99–1.09 0.10 0.91 0.82–1.00 0.06
aModels included both main effects and an interaction term for continuous birth year and categorical age at BMI and were adjusted for year at BMI
measurement. For females, the full cancer model includes 𝑁 = 518 cancers and 𝑁 = 2665 in the comparison. For males, the full cancer model includes
𝑁 = 542 cancers and𝑁 = 2745 in the comparison.
bUnderweight versus Normal-Obese.
cOverweight/Obese versus Underweight-Normal.
dFemale germ cell and male central nervous system not estimated as no cases were underweight in these cancer groups.
Bold indicates significant at 𝛼 < 0.05.
to believe survivors would report their weight differently
than the comparison, some survivors have poorer functional
health [42]. These survivors may have more difficulty with
day-to-day activities such as driving and, therefore, may
be less likely to obtain driver licenses. Thus, our results
may not reflect survivors with poorer health outcomes. In
addition, longitudinal studies are needed to provide detailed
information on the long-term risks for childhood cancer
survivors. Although we only had cross-sectional information
on BMI, our study reports on survivors diagnosed in recent
years. As such, our study expands on earlier cross-sectional
studies as more recent changes in treatment and long-term
management of childhood cancer patients are likely to be
reflected in our results. Finally, some studies have used clinic-
based, rather than population-based, ascertainment of cases
and used different comparison groups. Thus, our results may
be more generalizable than these studies as our cases and
comparison group were drawn from the same population.
5. Conclusions
In light of these data, childhood cancer patients and their
families can be reassured that cancer therapy is unlikely to
have a large impact on adult BMI.However, childhood cancer
survivors remain at risk for developing late effects that could
be exacerbated by an abnormal BMI, and 36% of female
and 61% of male survivors in Utah are overweight or obese.
Survivors have higher risk of developing diabetes, high blood
pressure and cholesterol, osteonecrosis, cardiovascular com-
plications, and stroke than the general population [43, 44].
Moreover, childhood cancer survivors often do not achieve
the recommended guidelines for physical activity [45] and
sustaining a healthy diet [46]. Given their susceptibility to
certain health problems, the high prevalence of overweight
and obesity that we observed among survivors of childhood
cancer, although similar to the general population, is of
concern. Diet, nutrition, and physical activity guidelines
for cancer survivors have been developed by the American
Cancer Society [47], yet most exercise and diet interventions
for childhood cancer survivors have had a modest impact on
behavior [48, 49].Thus, childhood cancer survivors can ben-
efit from access to resources to help them maintain a healthy
weight and to minimize their risk for late effects. Additional
research to identify effective strategies for promoting healthy
bodyweight tominimize late effects risk for childhood cancer
survivors is needed [15, 49].
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Table 4: Relative Risks (RR) and 95% Confidence Intervals (95% CI) of BMI outcomes for survivors by age at diagnosis, race, and treatment
therapy.
Main analysesa,c Secondary analysisb,c
Underweight (BMI < 18.5)3 Overweight/obese (BMI ≥ 25)3 Obese (BMI ≥ 30)3
RR 95% CI 𝑃-value RR 95% CI 𝑃-value RR 95% CI 𝑃-value
Female (𝑁 = 518)
Diagnosis age
16–20 (ref) 1 1 1
11–15 0.98 0.93–1.04 0.56 1.04 0.94–1.16 0.42 1.05 0.98–1.13 0.13
5–10 0.95 0.89–1.02 0.16 1.14 1.00–1.31 0.05 1.10 1.01–1.21 0.04
≤4 0.97 0.90–1.04 0.37 1.14 0.99–1.31 0.06 1.12 1.03–1.22 0.007
Race/ethnicity
Other (ref) 1 1 1
White, Non-Hispanic 1.09 1.04–1.15 0.001 0.95 0.75–1.21 0.67 1.11 1.04–1.19 0.002
Cancer therapy
Surgery (ref) 1 1 1
None or not documented 1.00 0.95–1.06 0.89 1.08 0.93–1.25 0.32 0.93 0.85–1.02 0.14
Chemotherapy 1.03 0.96–1.11 0.35 0.98 0.86–1.11 0.74 0.96 0.89–1.04 0.35
Radiation 1.06 0.97–1.16 0.17 0.99 0.84–1.15 0.88 0.97 0.88–1.08 0.62
Chemotherapy + radiation 1.01 0.96–1.07 0.67 1.15 0.99–1.34 0.06 0.97 0.88–1.07 0.62
Chemotherapy + surgery 1.08 0.94–1.24 0.26 1.05 0.87–1.27 0.61 0.90 0.84–0.96 0.001
Radiation + surgery 1.01 0.90–1.13 0.87 1.17 0.95–1.42 0.13 1.18 0.98–1.41 0.08
Chemotherapy + radiation + surgery 1.11 0.95–1.30 0.19 0.95 0.78–1.16 0.61 0.98 0.88–1.09 0.68
Male (𝑁 = 542)
Diagnosis age
16–20 (ref) 1 1 1
11–15 1.00 0.97–1.03 0.92 1.07 0.94–1.21 0.30 1.01 0.90–1.12 0.91
5–10 0.98 0.95–1.02 0.43 1.00 0.88–1.15 0.95 0.95 0.85–1.06 0.33
≤4 1.01 0.97–1.05 0.56 1.11 0.96–1.27 0.15 0.96 0.85–1.08 0.49
Race/ethnicity
Other (ref) 1 1 1
White, Non-Hispanic 0.94 0.80–1.10 0.44 0.94 0.72–1.22 0.64 1.03 0.93–1.28 0.79
Cancer therapy
Surgery (ref) 1 1 1
Chemotherapy 0.99 0.95–1.04 0.78 0.99 0.88–1.13 0.93 1.03 0.92–1.15 0.63
Radiation 1.00 0.96–1.04 0.94 0.98 0.83–1.16 0.83 1.14 0.97–1.34 0.11
Not documented/no treatment 1.03 0.97–1.10 0.28 1.01 0.86–1.19 0.88 1.09 0.94–1.26 0.23
Chemotherapy + radiation 0.99 0.94–1.04 0.71 0.91 0.78–1.05 0.21 0.97 0.86–1.09 0.59
Chemotherapy + surgery 0.99 0.94–1.04 0.74 1.01 0.85–1.20 0.93 1.00 0.87–1.14 0.98
Radiation + surgery 0.97 0.93–1.00 0.09 0.98 0.78–1.21 0.83 1.01 0.84–1.22 0.92
Chemotherapy + radiation + surgery 0.96 0.93–1.00 0.05 1.06 0.87–1.29 0.57 1.05 0.89–1.24 0.55
aMain analyses include two models; the first model compared underweight to all other BMI categories. The second model compared overweight/obese as one
category to all other BMI categories.
bSecondary analysis model compared obese to all other BMI categories.
cModels included both main effects and an interaction term for continuous birth year and categorical age at BMI and were adjusted for year at BMI
measurement.
Bold indicates significant at 𝛼 < 0.05.
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